A recent series of suspected overdoses involving the drug gamma-hydroxybutyrate (GHB) in Wellington has raised calls for increased drug testing to prevent further harm. The incidents, which occurred over the past week, resulted in one fatality and five hospitalizations.

The fatality took place at Woofingtons, a notable mansion in Wellington, where a woman reportedly consumed GHB from a bottle. According to a friend, the woman ingested the substance prior to her death, which triggered concerns about the safety and composition of drugs sold under similar names.

GHB belongs to a class of substances commonly referred to as "G-type" drugs, which also include gamma-butyrolactone (GBL) and 1,4-butanediol (14BD). These substances can sometimes be confused or deliberately misrepresented in the recreational drug market. Jason George, the national lead for harm reduction at the Drug Information and Support Centre (DISC) Trust, highlighted recent cases where one G-type substance was sold as another. He cited examples from the drug checking service in Wellington, including instances where GHB was sold as 14BD.

George explained that such mislabeling can lead users to consume larger quantities than intended, believing the drug is not working, only to experience delayed but intensified effects that increase the risk of overdose. He emphasized the narrow margin between a dose that produces desirable effects and one that causes serious harm, noting that differences of mere fractions of a millilitre can be critical.

In light of these events, harm reduction advocates are urging individuals to utilize drug checking services before consumption. George stressed that without testing, users cannot be certain of a substance’s identity, increasing the risks of unintended overdoses. By confirming the drug’s identity through testing, individuals can better understand what they are taking and potentially reduce the likelihood of adverse outcomes.

The recent Wellington cases underscore ongoing concerns about the circulation of unregulated G-type substances and their impact on public health. Authorities and harm reduction groups continue to promote awareness and the availability of testing as part of broader efforts to minimize drug-related harm in New Zealand.